<DOC>
	<DOCNO>NCT00205647</DOCNO>
	<brief_summary>This randonmized , mask , placebo-controlled parallel group , clinical trial evaluate effect three different dos N-acetyl L-cysteine ( NAC ) placebo patient safety physical transport property expectorate sputum . Patient sumptoms , quality life exacerbation also follow well pulmonary function test functional exercise capacity . We hypothesize prolongeed course oral NAC favorably affect morbidity chronic bronchitis , particularly incidence acute exacerbation .</brief_summary>
	<brief_title>Study Expectorant Activity Oral N-Acetylcystein ( NAC ) Patients With Stable Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Expectorants</mesh_term>
	<criteria>Smokers ( past current,20 pack year ) diagnosis chronic bronchitis expectorate sputum daily FEV1 4070 % understand fill questionnaire daily investigational within 30 day change smoke habit within 6 month pulmonary diagnosis chronic bronchitis significant renal , cardiac , hepatic endocrine disease psychiatric disorder evidence alcoholism drug abuse within year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>N-acetylcysteine ( NAC )</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Mucus</keyword>
</DOC>